Cart
sales@molnova.com
Methyl pentadecanoate
CAS No. 7132-64-1
Methyl pentadecanoate( methyl pentadecanoate )
Catalog No. M29410 CAS No. 7132-64-1
Methyl pentadecanoate is a natural product.Methyl pentadecanoate is a saturated fatty acid methyl ester obtained from the esterification of myristic acid. Methyl myristate shows a high melanin induction in B16F10 melanoma.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameMethyl pentadecanoate
-
NoteResearch use only, not for human use.
-
Brief DescriptionMethyl pentadecanoate is a natural product.Methyl pentadecanoate is a saturated fatty acid methyl ester obtained from the esterification of myristic acid. Methyl myristate shows a high melanin induction in B16F10 melanoma.
-
DescriptionMethyl pentadecanoate is a natural product.Methyl pentadecanoate is a saturated fatty acid methyl ester obtained from the esterification of myristic acid. Methyl myristate shows a high melanin induction in B16F10 melanoma.
-
In Vitro——
-
In Vivo——
-
Synonymsmethyl pentadecanoate
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number7132-64-1
-
Formula Weight256.43
-
Molecular FormulaC16H32O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 12.5 mg/mL (48.75 mM)
-
SMILESCCCCCCCCCCCCCCC(=O)OC
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
DPhPC
DPhPC is a synthetic liposome used to synthesize liposomes commonly used in artificial membrane matrices.
-
Onvatilimab
Onvatilimab (JNJ-61610588) is a human IgG1 κ-anti-Vista (T-cell-activated V-domain Ig inhibitor) monoclonal antibody with antitumor activity, potentially used for treating advanced head and neck cancers.
-
[Pro3]-GIP (Mouse)
GIP receptor antagonist (IC50 = 2.6μM). Inhibits GIP-stimulated insulin release from pancreatic β cells in vitro. In ob/ob mice, blocks the effects of GIP on insulin release and plasma glucose levels. Also improves intraperitoneal glucose tolerance, insulin sensitivity, and glucose response to feeding in ob/ob mice.
